APTIS BIO
Design Modalities Computational Pipeline Contact Us Request a Design Study

Privacy Policy

Effective Date: November 2026 • Aptis Bio

Aptis Bio ("we," "our," or "us") respects the confidentiality and privacy of our prospective clients, research partners, and website visitors. This Privacy Policy describes how we collect, use, and safeguard information submitted through our website.

1. Information We Collect

  • Business Contact Information: Name, organization, work email address, and project scope details voluntarily submitted through our study inquiry or contact forms.
  • Non-Confidential Target Metadata: Public target identifiers (such as PDB codes or UniProt accession numbers) provided during initial feasibility scoping.
  • Technical Logs: Standard web server access logs (IP address, browser user-agent, timestamps) used strictly for security monitoring and service reliability.

2. How We Use Information

We use submitted information exclusively to evaluate computational design feasibility, prepare study proposals, execute mutual Confidential Disclosure Agreements (CDAs), and communicate regarding active or prospective research engagements. All form inquiries are dispatched to service@m2kbio.com. We do not sell, rent, or trade contact or project data to third parties.

3. Scientific Data & Confidentiality

Please do not submit proprietary antigen sequences, unpublished crystal structures, or confidential assay data through public web forms prior to executing a bilateral CDA with Aptis Bio. Once a CDA is executed, all target data and generated designs are governed by the strict confidentiality and data-isolation terms of that agreement.

4. Data Security & Retention

Inquiries are transmitted over encrypted TLS connections and stored within access-controlled infrastructure. You may request access to, correction of, or deletion of your contact records at any time via our Contact Us page.

Privacy Policy | Terms of Service | Contact Us

© 2026 Aptis Bio. Computational Biologics & De Novo Molecular Design.